MannKind inks deal to bring inhaled insulin to Brazil

MannKind Corp. (NSDQ:MNKD) said today that inked a supply and distribution deal with Biomm for the commercialization of its inhaled insulin, Afrezza, in Brazil.

According to the agreement, Biomm will prepare and file the necessary applications for regulatory approval. MannKind will be responsible for manufacturing and supplying Afrezza and Biomm is slated to promote and distribute the product within Brazil.

Get the full story at our sister site, Drug Delivery Business News.

The post MannKind inks deal to bring inhaled insulin to Brazil appeared first on MassDevice.

from MassDevice http://ift.tt/2rgiK3d